Effect of thalidomide on gastrointestinal toxic effects of irinotecan
Effect of thalidomide on gastrointestinal toxic effects of irinotecan
复制标题
DOI：
10.1016/s0140-6736(00)02586-1
复制
发表时间：
2000-08-12
期刊：
影响因子：
168.9
通讯作者：
Hauer-Jensen, M
中科院分区：
文献类型：
--
作者：
Govindarajan, R;Heaton, KM;Hauer-Jensen, M
伊立替康是美国唯一被接受的结直肠癌二线治疗药物。然而，剂量往往受到相关的迟发性腹泻的限制。沙利度胺具有抗血管生成和免疫调节作用，目前正在作为一种抗肿瘤药物进行研究。我们进行了沙利度胺和伊立替康联合治疗转移性结直肠癌的初步研究。在一项对9名患者的中期分析中，沙利度胺几乎消除了伊立替康的限量胃肠道毒性，特别是腹泻和恶心(各P
Irinotecan is the only accepted second-line treatment for colorectal cancer in the USA. Doses are, however, frequently limited by associated late-onset diarrhoea. Thalidomide has antiangiogenic and immunomodulatory properties and is being investigated as an antineoplastic. We did a pilot study of combination therapy with thalidomide and irinotecan for metastatic colorectal cancer. In an interim analysis of nine patients, thalidomide had almost eliminated the dose-limiting gastrointestinal toxic effects of irinotecan, especially diarrhoea and nausea (each p